The present invention relates to processes for the preparation of rosiglitazone rosiglitazone prepared thereby and pharmaceutical compositions and therapeutic uses thereof and methods of treatment employing the same.

The present invention relates to a pharmaceutical composition for the treatment of type 2 diabetes in mammals including human beings, wherein the pharmaceutical composition contains (3aS, 5s, 6aR)-5-(2-((2S, 4S)-2-cyano-4-fluoropyrrolidine-1-yl)-2-oxo-ethylamino)-N, N, 5-trimethyl-hexahydro-cyclopenta[C]pyrrole-2(1H)-carboxamide or its pharmaceutically acceptable salts and rosiglitazone or pioglitazone or their pharmaceutically acceptable salts, preparation method thereof and a method of treatin...

The present invention relates to methods and compositions for treating type II diabetes. This invention discloses an orally administrable pharmaceutical formulation, as convenient therapy to reduce glucose levels in blood, preventing the development of diabetes and an earlier exhausting of the pancreas. In certain embodiments, the invention provides orally administerable combination pharmaceutical formulations, comprising at least one insulin sensitizer (e.g., a glitazone such as pioglitazone or...

The present invention relates to methods and compositions for treating type II diabetes. This invention discloses an orally administrable pharmaceutical formulation as convenient therapy to reduce glucose levels in blood preventing the development of diabetes and an earlier exhausting of the pancreas. In certain embodiments the invention provides orally administerable combination pharmaceutical formulations comprising at least one insulin sensitizer (e.g. a glitazone such as pioglitazone or rosi...

Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula (I) where x is 0 or 1 and y is 0 or 1 (provided that x = 1 when y = 0 and x = 0 when y = 1); n is 0 or 1; X is H or CN; and wherein R1 R2 R3 and R4 are as described herein. A method is also provided for treating diabetes and related diseases especially Type II diabetes and other diseases as set out herein employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic...